
    
      This is a multicenter, open-label study. A total of 80 patients are treated on this study and
      include:

      At least 30 patients with a viral burden of 500 - 40,000 copies/ml. At least 30 patients with
      a viral burden greater than 40,000 copies/ml. At least 20 patients with less than 1 year
      total prior treatment with nucleoside reverse transcriptase inhibitors (NRTIs).

      All patients receive self-administered, combination antiretroviral therapy for 48 weeks, as
      follows:

      1592U89 plus 141W94 plus DMP 266.
    
  